Ensysce Biosciences (ENSCW) Receivables - Other (2021 - 2025)
Ensysce Biosciences (ENSCW) reported Receivables - Other of $420345.0 for Q4 2025, up 238.67% year-over-year from $124115.0 in Q4 2024, and up 9429.47% quarter-over-quarter from $4411.0 in Q3 2025.
Ensysce Biosciences (ENSCW) Receivables - Other (2021 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 5 years of Receivables - Other data on file, last reported at $420345.0 in Q4 2025.
- Receivables - Other for Q4 2025 came in at $420345.0, up 238.67% year-over-year; the trailing twelve-month figure through Dec 2025 was $420345.0 (up 238.67% YoY), and the FY2025 annual result was $420345.0, up 238.67% from the prior year.
- Receivables - Other climbed to $420345.0 in Q4 2025 per ENSCW's latest filing, from $4411.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $1.8 million in Q3 2024 and troughed at $4411.0 in Q3 2025.
- A 5-year average of $346742.2 and a median of $140813.0 in 2022 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2024 and 2025: Receivables - Other jumped 1554.76% in 2024, then tumbled 99.75% in 2025.
- A 5-year view of Receivables - Other shows it stood at $441721.0 in 2021, then plunged by 37.33% to $276821.0 in 2022, then sank by 64.76% to $97561.0 in 2023, then rose by 27.22% to $124115.0 in 2024, then jumped by 238.67% to $420345.0 in 2025.
- Business Quant data shows ENSCW's Receivables - Other at $420345.0 in Q4 2025, $4411.0 in Q3 2025, and $1.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ensysce Biosciences | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 420,345.00 |
| Dec 31, 2025 | 420,345.00 |
| Sep 30, 2025 | 4,411.00 |
| Sep 30, 2025 | 4,411.00 |
| Jun 30, 2025 | 1.20 Mn |
| Jun 30, 2025 | 1.20 Mn |
| Mar 31, 2025 | 22,002.00 |
| Mar 31, 2025 | 22,002.00 |
| Dec 31, 2024 | 124,115.00 |
| Dec 31, 2024 | 124,115.00 |
| Sep 30, 2024 | 1.78 Mn |
| Sep 30, 2024 | 1.78 Mn |
| Jun 30, 2024 | 224,223.00 |
| Jun 30, 2024 | 224,223.00 |
| Mar 31, 2024 | 96,224.00 |
| Mar 31, 2024 | 96,224.00 |
| Dec 31, 2023 | 97,561.00 |
| Dec 31, 2023 | 97,561.00 |
| Sep 30, 2023 | 107,738.00 |
| Sep 30, 2023 | 107,738.00 |